News
Dr. Sahin gave a talk on “Targeting LOX in chemoresistance and developing novel LOX inhibitors” at the ACS Mini Symposium
Dr. Sahin co-organized a Mini Symposium with Dr. Taru Muranen (Dana-Farber Cancer Institute) and Rebeca San Martin (University of Tennessee, Knoxville) which was hosted by Joe Cotter from the American Cancer Society – February 17, 2021. The Mini Symposium was on “Tumor microenvironment in the context of drug resistance and metastasis”. Dr. Sahin Presented our work targeting ECM remodeler LOX to overcome chemoresistance in TNBC and developing novel LOX inhibitors. This virtual meeting hosted more Read more…
News
Dr. Sahin presents “From mechanisms of resistance to drug discovery” at IBG Seminer Series
Dr. Sahin presented our recent work on how we take genome/transcriptome-wide approaches to identify regulators of drug resistance, identify mechanisms of resistance and develop novel drug candidates on Feb 12, 2021 at the Seminar Series of Izmir Biomedicine and Genome Center (IBG), which is a leading biomedical center in Turkey.
News
Dr. Sahin presents a “Lightning Talk” at AACR Virtual Special Congress
AACR Virtual Special Congress, “The Evolving Tumor Microenvironment in Cancer Progression; Mechanisms and Emerging Therapeutic Opportunities” – January 11-12, 2021, brought together experts from diverse fields to thoroughly explore and discuss the topic. Dr. Sahin gave a “Lightning Talk” on the role of LOX in chemoresistance.
News
Dr. Sahin gives a talk at the Multidisciplinary Cancer Research Congress
Dr. Sahin gave a talk entitled “From mechanisms of drug resistance to drug discovery” at the 8th Multidisciplinary Cancer Research Congress held by Istinye University, Istanbul – January 16, 2021. The talk was well received by the audience with multiple questions and comments from students to experts in the field.
News
Dr. Sahin presents our project on targeting LOX in TNBC at the National NIGMS IDeA PI Meeting
Our project aiming at overcoming chemotherapy resistance in TNBC via targeting lysyl oxidase (LOX) was chosen for presentation at National NIGMS IDeA Program Virtual Meeting – September 22, 2020. Our discovery of this novel drug resistance mechanism was recently published in one of the most selective and prestigious scientific journals (Nature Communications). We are hopeful that our findings will pave the way to develop novel drugs targeting LOX for the treatment of TNBC that do Read more…
Publication
Our new paper is published in Nature Communications
Our latest article has been published in Nature Communications. The study focuses on the identification of lysyl oxidase (LOX) protein as a major chemotherapy resistance modulator in triple negative breast cancer. We showed that targeting LOX overcomes chemoresistance in TNBC. Read the article here.